Mechanisms of resistance to FGFR1 inhibitors in FGFR1-driven leukemias and lymphomas: implications for optimized treatment

Abstract

Myeloid and lymphoid neoplasms with eosinophilia and FGFR1 rearrangements (MLN-eo FGFR1) disease is derived from a pluripotent hematopoietic stem cell and has a complex presentation with a myeloproliferative disorder with or without eosinophilia and frequently presents with mixed lineage T- or B-lymphomas. The myeloproliferative disease frequently progresses to AML and lymphoid neoplasms can develop into acute lymphomas. No matter the cell type involved, or clinical presentation, chromosome translocations involving the FGFR1 kinase and various partner genes, which leads to constitutive activation of downstream oncogenic signaling cascades. These patients are not responsive to treatment regimens developed for other acute leukemias and survival is poor. Recent development of specific FGFR1 inhibitors has suggested an alternative therapeutic approach but resistance is likely to evolve over time. Mouse models of this disease syndrome have been developed and are being used for preclinical evaluation of FGFR1 inhibitors. Cell lines from these models have now been developed and have been used to investigate the mechanisms of resistance that might be expected in clinical cases. So far, a V561M mutation in the kinases domain and deletion of PTEN have been recognized as leading to resistance and both operate through the PI3K/AKT signaling axis. One of the important consequences is the suppression of PUMA, a potent enforcer of apoptosis, which operates through BCL2. Targeting BCL2 in the resistant cells leads to suppression of leukemia development in mouse models, which potentially provides an opportunity to treat patients that become resistant to FGFR1 inhibitors. In addition, elucidation of molecular mechanisms underlying FGFR1-driven leukemias and lymphomas also provides new targets for combined treatment as another option to bypass the FGFR1 inhibitor resistance and improve patient outcome.

Keywords

MLN-eo FGFR1 / lymphomas / FGFR1 / mutations / PTEN / PUMA / mouse models

References

[1] Abruzzo LV,Cotelingam JD,Del Duca V Jr.T-cell lymphoblastic lymphoma with eosinophilia associated with subsequent myeloid malignancy.Am J Surg Pathol1992;16:236-45

[2] Macdonald D,Mason PJ,Cross NC.A new myeloproliferative disorder associated with chromosomal translocations involving 8p11: a review.Leukemia1995;9:1628-30

[3] Inhorn RC,Roach SA.A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity.Blood1995;85:1881-7

[4] Patnaik MM,Knudson RA.Chromosome 8p11.2 translocations: prevalence, FISH analysis for FGFR1 and MYST3, and clinicopathologic correlates in a consecutive cohort of 13 cases from a single institution.Am J Hematol2010;85:238-42

[5] Savage N,Gotlib J.Myeloid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, and FGFR1: a review.Int J Lab Hematol2013;35:491-500

[6] Reiter A.Myeloid neoplasms with eosinophilia.Blood2017;129:704-14

[7] Kasbekar M,Dal Cin P.Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia.Blood Adv2020;4:3136-40 PMCID:PMC7362377

[8] Vega F,Davuluri R,Alkan S.t(8;13)-positive bilineal lymphomas: report of 6 cases.Am J Surg Pathol2008;32:14-20

[9] Jackson CC,Miranda RN.8p11 myeloproliferative syndrome: a review.Hum Pathol2010;41:461-76

[10] Vardiman JW,Arber DA.The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.Blood2009;114:937-51

[11] Arber DA,Hasserjian R.The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.Blood2016;127:2391-405

[12] Demiroglu A,Heath C.The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins.Blood2001;98:3778-83

[13] Haslam K,Kelly J,O'Connell NM.Allogeneic hematopoietic stem cell transplantation for a BCR-FGFR1 myeloproliferative neoplasm presenting as acute lymphoblastic leukemia.Case Rep Hematol2012;2012:620967 PMCID:PMC3467796

[14] Montenegro-Garreaud X,Reynolds A.Myeloproliferative neoplasms with t(8;22)(p11.2;q11.2)/BCR-FGFR1: a meta-analysis of 20 cases shows cytogenetic progression with B-lymphoid blast phase.Hum Pathol2017;65:147-56

[15] Konishi Y,Nakao K.Allogeneic hematopoietic stem cell transplantation for 8p11 myeloproliferative syndrome with BCR-FGFR1 gene rearrangement: a case report and literature review.Bone Marrow Transplant2019;54:326-9

[16] Kim SY,She CJ.8p11 Myeloproliferative syndrome with BCR-FGFR1 rearrangement presenting with T-lymphoblastic lymphoma and bone marrow stromal cell proliferation: a case report and review of the literature.Leuk Res2011;35:e30-4

[17] Murati A,Lafage-Pochitaloff M.Dual lympho-myeloproliferative disorder in a patient with t(8;22) with BCR-FGFR1 gene fusion.Int J Oncol2005;26:1485-92

[18] Umino K,Ikeda T.Clinical outcomes of myeloid/lymphoid neoplasms with fibroblast growth factor receptor-1 (FGFR1) rearrangement.Hematology2018;23:470-7

[19] IH Cowell JK. The t(8;13) atypical myeloproliferative disorder: further analysis of the ZNF198 gene and lack of evidence for multiple genes disrupted on chromosome 13.Blood1998;92:1456-8

[20] Grand EK,Chase AJ.Identification of a novel gene, FGFR1OP2, fused to FGFR1 in 8p11 myeloproliferative syndrome.Genes Chromosomes Cancer2004;40:78-83

[21] Guasch G,Popovici C.FGFR1 is fused to the centrosome-associated proteinCEP110 in the 8p12 stem cell myeloproliferative disorder with t(8;9)(p12;q33).Blood2000;95:1788-96

[22] Chen M,Cai X.Myeloid/lymphoid neoplasm with CEP110-FGFR1 fusion: An analysis of 16 cases show common features and poor prognosis.Hematology2021;26:153-9

[23] Fioretos T,Lassen C.Fusion of the BCR and the fibroblast growth factor receptor-1 (FGFR1) genes as a result of t(8;22)(p11;q11) in a myeloproliferative disorder: the first fusion gene involving BCR but not ABL.Genes Chromosomes Cancer2001;32:302-10

[24] Smedley D,Abdul-Rauf M.ZNF198-FGFR1 transforms Ba/F3 cells to growth factor independence and results in high level tyrosine phosphorylation of STATS 1 and 5.Neoplasia1999;1:349-55 PMCID:PMC1508104

[25] Baumann H,Tracy E.The oncogenic fusion protein-tyrosine kinase ZNF198/fibroblast growth factor receptor-1 has signaling function comparable with interleukin-6 cytokine receptors.J Biol Chem2003;278:16198-208

[26] Heath C.Critical role of STAT5 activation in transformation mediated by ZNF198-FGFR1.J Biol Chem2004;279:6666-73

[27] Chong Y,Lu S.Critical individual roles of the BCR and FGFR1 kinase domains in BCR-FGFR1-driven stem cell leukemia/lymphoma syndrome.Int J Cancer2020;146:2243-54

[28] Goradia A,Cornfield D.The 8p11 myeloproliferative syndrome: review of literature and an illustrative case report.Int J Clin Exp Pathol2008;1:448-56 PMCID:PMC2480578

[29] Agerstam H,Lassen C.Fusion gene-mediated truncation of RUNX1 as a potential mechanism underlying disease progression in the 8p11 myeloproliferative syndrome.Genes Chromosomes Cancer2007;46:635-43

[30] Strati P,Duose DY.Myeloid/lymphoid neoplasms with FGFR1 rearrangement.Leuk Lymphoma2018;59:1672-6

[31] Verstovsek S,Masarova L.Treatment of the myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor.Ann Oncol2018;29:1880-2 PMCID:PMC6887683

[32] Khodadoust MS,Medeiros BC.Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia.Leukemia2016;30:947-50 PMCID:PMC5369353

[33] Chase A,Cross NC.Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome.Blood2007;110:3729-34

[34] Chen J,Kutok JL.PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder.Proc Natl Acad Sci U S A2004;101:14479-84 PMCID:PMC521956

[35] Roumiantsev S,Neumann CA.Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations.Cancer Cell2004;5:287-98

[36] Ren M,Cowell JK.Genetic fingerprinting of the development and progression of T-cell lymphoma in a murine model of atypical myeloproliferative disorder initiated by the ZNF198-fibroblast growth factor receptor-1 chimeric tyrosine kinase.Blood2009;114:1576-84 PMCID:PMC2731638

[37] Ren M,Sharma S.Acute progression of BCR-FGFR1 induced murine B-lympho/myeloproliferative disorder suggests involvement of lineages at the pro-B cell stage.PLoS One2012;7:e38265 PMCID:PMC3368885

[38] Ren M,Kitamura E.Dysregulated signaling pathways in the development of CNTRL-FGFR1-induced myeloid and lymphoid malignancies associated with FGFR1 in human and mouse models.Blood2013;122:1007-16 PMCID:PMC3739028

[39] Ren M.Constitutive Notch pathway activation in murine ZMYM2-FGFR1-induced T-cell lymphomas associated with atypical myeloproliferative disease.Blood2011;117:6837-47 PMCID:PMC3128478

[40] Qin H,Cowell JK.FGFR1OP2-FGFR1 induced myeloid leukemia and T-cell lymphoma in a mouse model.Haematologica2016;101:e91-4 PMCID:PMC4815735

[41] Cowell JK,Chang CS,Ren M.A model of BCR-FGFR1 driven human AML in immunocompromised mice.Br J Haematol2016;175:542-5 PMCID:PMC5609710

[42] Ren M,Wu Q,George TI.Development of ZMYM2-FGFR1 driven AML in human CD34+ cells in immunocompromised mice.Int J Cancer2016;139:836-40 PMCID:PMC5754922

[43] Gu TL,Reeves C.Phosphotyrosine profiling identifies the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemia.Blood2006;108:4202-4

[44] Furley AJ,Mizutani S.Divergent molecular phenotypes of KG1 and KG1a myeloid cell lines.Blood1986;68:1101-7

[45] Wakim JJ,Chen W.t(8;22)/BCR-FGFR1 myeloproliferative disorder presenting as B-acute lymphoblastic leukemia: report of a case treated with sorafenib and review of the literature.Leuk Res2011;35:e151-3

[46] Gozgit JM,Moran L.Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.Mol Cancer Ther2012;11:690-9

[47] Ren M,Ren R.Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities.Leukemia2013;27:32-40 PMCID:PMC3629706

[48] Guagnano V,Spanka C.Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.J Med Chem2011;54:7066-83

[49] Perera TPS,Mevellec L.Discovery and pharmacological characterization of JNJ-42756493 (Erdafitinib), a functionally selective small-molecule FGFR family inhibitor.Mol Cancer Ther2017;16:1010-20

[50] Gavine PR,Kilgour E.AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.Cancer Res2012;72:2045-56

[51] Wu Q,Qin H.SCLLTargeting FGFR1 to suppress leukemogenesis in syndromic and de novo AML in murine models.Oncotarget2016;7:49733-42 PMCID:PMC5226543

[52] Cowell JK,Hu T,Bhole A.Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1-driven leukemia/lymphomas.Int J Cancer2017;141:1822-9 PMCID:PMC5850950

[53] Bhullar KS,McGowan EM.Kinase-targeted cancer therapies: progress, challenges and future directions.Mol Cancer2018;17:48 PMCID:PMC5817855

[54] Bello E,Scarlato V.E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models.Cancer Res2011;71:1396-405

[55] Sohl CD,Luo B,Anderson KS.Illuminating the molecular mechanisms of tyrosine kinase inhibitor resistance for the FGFR1 gatekeeper mutation: the Achilles' heel of targeted therapy.ACS Chem Biol2015;10:1319-29 PMCID:PMC4533833

[56] Georgescu MM.PTEN Tumor suppressor network in PI3K-Akt pathway control.Genes Cancer2010;1:1170-7 PMCID:PMC3092286

[57] Liu Y,Chong Y.Downregulation of PUMA underlies resistance to FGFR1 inhibitors in the stem cell leukemia/lymphoma syndrome.Cell Death Dis2020;11:884 PMCID:PMC7576156

[58] Yu J.PUMA, a potent killer with or without p53.Oncogene2008;27 Suppl 1:S71-83

[59] Jeffers JR,Lee Y.Puma is an essential mediator of p53-dependent and -independent apoptotic pathways.Cancer Cell2003;4:321-8

[60] You H,Tsuchihara K.FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal.J Exp Med2006;203:1657-63 PMCID:PMC2118330

[61] Dudgeon C,Sun X.PUMA induction by FoxO3a mediates the anticancer activities of the broad-range kinase inhibitor UCN-01.Mol Cancer Ther2010;9:2893-902 PMCID:PMC2978764

[62] Souers AJ,Boghaert ER.ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.Nat Med2013;19:202-8

[63] Peirs S,Goossens S.ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia.Blood2014;124:3738-47

[64] Bean GR,Dong Y.PUMA and BIM are required for oncogene inactivation-induced apoptosis.Sci Signal2013;6:ra20 PMCID:PMC3753585

[65] Garrison SP,Jeffers JR.Genetically defining the mechanism of Puma- and Bim-induced apoptosis.Cell Death Differ2012;19:642-9 PMCID:PMC3307979

[66] Erlacher M,Manzl C.Puma cooperates with Bim, the rate-limiting BH3-only protein in cell death during lymphocyte development, in apoptosis induction.J Exp Med2006;203:2939-51 PMCID:PMC2118188

[67] Zhang LN,Xu W.A review of the role of Puma, Noxa and Bim in the tumorigenesis, therapy and drug resistance of chronic lymphocytic leukemia.Cancer Gene Ther2013;20:1-7

[68] Dijkers PF,Lammers JJ,Coffer PJ.Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1.Current Biology2000;10:1201-4

[69] Hu T,Chong Y.FGFR1 fusion kinase regulation of MYC expression drives development of stem cell leukemia/lymphoma syndrome.Leukemia2018;32:2363-73 PMCID:PMC6168426

[70] Moore G,McClements L.Top notch targeting strategies in cancer: a detailed overview of recent insights and current perspectives.Cells2020;9:1503 PMCID:PMC7349363

[71] Ren M,Ren R,Cowell JK.Src activation plays an important key role in lymphomagenesis induced by FGFR1 fusion kinases.Cancer Res2011;71:7312-22 PMCID:PMC3228896

[72] Hu T,Lu S.Loss of the BCR-FGFR1 GEF domain suppresses RHOA activation and enhances B-lymphomagenesis in mice.Cancer Res2019;79:114-24 PMCID:PMC6484845

[73] Hu T,Cai B,Lu S.DNA methyltransferase 1-mediated CpG methylation of the miR-150-5p promoter contributes to fibroblast growth factor receptor 1-driven leukemogenesis.J Biol Chem2019;294:18122-30 PMCID:PMC6885633

[74] Sun X,Gunawan S.Selective inhibition of leukemia-associated SHP2^E69K mutant by the allosteric SHP2 inhibitor SHP099.Leukemia2018;32:1246-9 PMCID:PMC6166654

[75] Chen YN,Chan HM.Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.Nature2016;535:148-52

[76] Hu T,Lu S,Williams DA.Rac1/2 activation promotes FGFR1 driven leukemogenesis in stem cell leukemia/lymphoma syndrome.Haematologica2020;105:e68-71 PMCID:PMC7012474

[77] Montalvo-Ortiz BL,Hernández E.Characterization of EHop-016, novel small molecule inhibitor of Rac GTPase.J Biol Chem2012;287:13228-38 PMCID:PMC3339933